众生药业：RAY1225注射液两项降糖III期临床试验完成首例参与者入组

Core Viewpoint - The announcement highlights that the innovative peptide drug RAY1225 injection, developed by the subsidiary Zhongsheng Ruichuang, has completed the enrollment and administration of the first participant in two Phase III clinical trials for glucose-lowering treatment [1] Group 1 - RAY1225 injection possesses global independent intellectual property rights and has the potential for long-acting administration with an injection every two weeks [1] - Zhongsheng Ruichuang will continue to advance the Phase III clinical trials of RAY1225 injection, aiming to complete the relevant research and apply for drug market approval as soon as possible [1]